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Abstract: The determination of the sample size required by a crossover trial typically depends on the
specification of one or more variance components. Uncertainty about the value of these parameters at
the design stage means that there is often a risk a trial may be under- or over-powered. For many study
designs, this problem has been addressed by considering adaptive design methodology that allows for the
re-estimation of the required sample size during a trial. Here, we propose and compare several approaches
for this in multi-treatment crossover trials. Specifically, regulators favour re-estimation procedures to
maintain the blinding of the treatment allocations. We therefore develop blinded estimators for the
within and between person variances, following simple or block randomisation. We demonstrate that,
provided an equal number of patients are allocated to sequences that are balanced for period, the
proposed estimators following block randomisation are unbiased. We further provide a formula for the
bias of the estimators following simple randomisation. The performance of these procedures, along with
that of an unblinded approach, is then examined utilising three motivating examples, including one
based on a recently completed four-treatment four-period crossover trial. Simulation results show that
the performance of the proposed blinded procedures is in many cases similar to that of the unblinded
approach, and thus they are an attractive alternative.
Keywords: Blinded; Crossover trial; Internal pilot study; Sample size re-estimation.
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1. Introduction
Crossover trials, in which participants are randomly allocated to receive a sequence of treatments across a
series of time periods, are an extremely useful tool in clinical research. Their nature permits each patient
to act as their own control, exploiting the fact that in most instances the variability of measurements on
different subjects in a study will be far greater than that on the same subject. In this way, crossover trials
are often more efficient than parallel group trials. Like most experimental designs, the determination of
the sample size required by a crossover trial, to achieve a certain power for a particular treatment effect,
depends on the significance level, and at least one factor which accounts for the participant’s variance
in response to treatment. Whilst the former are designated quantities, the variance factors will usually
be subject to substantial uncertainty at the design stage. Their value will often be greatly affected by
components of the current trial, such as inclusion/exclusion criteria for example, that renders estimates
obtained from previous trials biased. This is troubling since sample size calculation is of paramount
importance in study design. Planning a trial that is too large results in an unnecessary number of
patients being made susceptible to interventions that may be harmful. It also needlessly wastes valuable
resources in terms of time, money, and available trial participants. In contrast, too small a sample size
confers little chance of success for a trial. The consequences of this could be far reaching: a wrong
decision may lead to the halting of the development of a therapy, which could deprive future patients of
a valuable treatment option.
To address this problem in a parallel group setting with normally distributed outcome variables,
Wittes and Brittain [30], building upon previous work by Stein [27], proposed the internal pilot study
design. In their approach, at an interim time period the accrued data is unblinded, the within-group
variance computed, and the trial’s required sample size adjusted if necessary. However, unblinding an
ongoing trial can reduce its integrity and introduce bias [13]. Consequently, Gould and Shih [12] explored
several approaches for re-estimating the required sample size in a blinded manner. Since then, a number
of papers have advocated for re-estimation in a parallel group setting to be based upon a crude one-sample
estimate of the variance, and methodology has also been proposed which allows the type-I error-rate to
be more accurately controlled [17]. More recently, much work has been conducted on similar methods
for an array of possible trial designs and types of outcome variable (see, e.g., Jensen and Kieser [14] and
Togo and Iwasaki [28]), with these methods also gaining regulatory acceptance [2, 5].
Thus, today, sample size re-estimation procedures have established themselves for parallel group trials
as an advantageous method to employ when there is pre-trial uncertainty over the appropriate sample size.
In contrast, there has been little exploration of such methodology within the context of multi-treatment
crossover trials. Golkowski et al. [11] recently explored a blinded sample size re-estimation procedure
for establishing bioequivalence in a trial utilising an AB/BA crossover design. Jones and Kenward [15]
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discussed how the results of Kieser and Friede [17] could be rephrased for an AB/BA crossover trial testing
for superiority. In addition, several unblinded re-estimation procedures for AB/BA bioequivalence trials
have been proposed [22, 21, 32], the performance of which has recently been extensively compared [18].
The work of Lake et al. [19] and van Schie and Moerbeek [29] on sample size re-estimation in cluster
randomised trials has some parallels with the methodology required for crossover trials, because of the
necessitated mixed model for data analysis. Likewise, this is true of the methodology presented by Zucker
and Denne [33] on re-estimation procedures for longitudinal trials. However, we are unaware of any article
that explicitly discusses re-estimation in crossover trials with more than two-treatments. There are many
examples of such trials in the literature, whilst they also remain the focus of much research (see, e.g.,
Bailey and Druilhet [1] and, Lui and Chang [20]).
In this article, we consider several possible approaches to the interim re-assessment of the sample
size required by a multi-treatment crossover trial. We assume a normally distributed outcome variable,
and that a commonly utilised linear mixed model will be employed for data analysis. We focus pri-
marily on a setting in which the final analysis is based on many-to-one comparisons for one-sided null
hypotheses, but provide additional guidance for other possibilities in the Appendix. Blinded procedures
for estimating the between and within person variance in response are proposed, following either simple
or block randomisation to sequences that are balanced for period. The performance of these estimators is
contrasted to that of an unblinded procedure via a simulation study motivated by a real four-treatment
four-period crossover trial. Additionally, in the Appendix we provide results for two additional examples.
We now proceed by specifying the notation used in the re-estimation procedures. Our findings are then
summarised in Section 3, before we conclude in Section 4 with a discussion.
2. Methods
2.1. Hypotheses, notation, and analysis
We consider a crossover trial with D treatments, indexed d = 0, . . . , D − 1. Treatments d = 1, ..., D − 1
are considered experimental, and are to be compared to the common control d = 0. We suppose that K
sequences, indexed k = 1, . . . ,K, are utilised for treatment allocation, and denote by nk the number of
patients allocated to sequence k. The number of periods in the trial, which is equal to the length of each
of the sequences, is denoted by P .
We restrict our focus to trials with normally distributed outcome data, to be analysed using the
following linear mixed model
yijk = µ0 + pij + τd(j,k) + sik + ijk, i = 1, . . . , nk, j = 1, . . . , P, k = 1, . . . ,K. (2.1)
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Here
• yijk is the response for individual i, in period j, on sequence k;
• µ0 is an intercept term; the mean response on treatment 0 in period 1;
• pij is a fixed effect for period j, with the identifiability constraint pi1 = 0;
• τd(j,k) is a fixed direct treatment effect for the treatment administered to an individual in period j,
on sequence k, with the identifiability constraint τ0 = 0. Thus d(j, k) = 0, . . . , D − 1;
• sik ∼ N(0, σ2b ) is a random effect for individual i on sequence k;
• ijk ∼ N(0, σ2e) is the residual for the response from individual i, in period j, on sequence k.
This model, and its implied covariance structure, is the standard for a crossover trial that ignores the
possible effects of carryover. Thus we are implicitly heeding the advice of Senn [26], and others, that a
crossover trial should not be conducted when carryover is likely to be an issue. Furthermore, note that
by the above, two observations yi1j1k1 and yi2j2k2 are independent unless i1 = i2 and k1 = k2.
We assume that the following hypotheses are to be tested, to attempt to establish the superiority of
each experimental intervention versus the control
H0d : τd ≤ 0, H1d : τd > 0, d = 1, . . . , D − 1.
Note though that for Examples 1 and 3, slightly different hypotheses are assessed, as negative effects
imply efficacy. Additionally, in the Appendix we detail how one can handle alternate hypotheses of
interest.
We suppose that it is desired to strongly control the FWER, the maximal probability of one or more
incorrect rejections amongst the family of null hypotheses for all possible treatment effects, to some
specified level α ∈ (0, 1). There are several possible ways to define power in a multi-treatment setting.
Throughout, we assume that pairwise power of at least 1−β ∈ (0, 1) to reject, without loss of generality,
H01 is required when τ1 = δ > 0 for designated type-II error-rate β and clinically relevant difference δ.
Thus, from here, when referring to power we mean the probability that H01 is rejected. However, in the
Appendix we describe how a desired familywise power could be achieved.
To test the hypotheses, we assume that N patients in total will be recruited to the trial, with each
randomised to one of the K sequences, and that the the linear mixed model (2.1) will be fitted to
the accumulated data. Note that in fitting this model, a choice must be made over whether to utilise
maximum likelihood, or restricted error maximum likelihood (REML), estimation. Given the bias of the
maximum likelihood estimator of the variance components of a linear mixed model in finite samples,
and that crossover trials are often conducted with relatively small sample sizes, here we always take the
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latter approach. Note though that this would have little effect for larger sample sizes. For further details
on these considerations, we refer the reader to, for example, Fitzmaurice et al. [6]. In brief, the REML
estimation procedure, for a linear mixed model of the form y = Xβ + Zb +  with b ∼ N(0,G) and
 ∼ N(0,R), iteratively optimizes the parameter estimates for the effects in the model. The following
modified log-likelihood is maximised to provide an estimate, Σˆ, for Σ = ZGZ> +R, using an estimate,
βˆ, for β
−1
2
log |Σ| − 1
2
(y −Xβˆ)>Σ−1(y −Xβˆ)− 1
2
log |X>Σ−1X|.
Then, βˆ is updated to
βˆ = (X>Σˆ
−1
X)−1X>Σˆ
−1
y,
and the process repeated. Given the final solutions βˆ and Σˆ, we take Var(βˆ) = (X>Σˆ
−1
X)−1.
In our case, β = (µ0, pi2, . . . , piP , τ1, . . . , τD−1)>, and the following D − 1 Wald test statistics are
formed
Td =
τˆd√
Var(τˆd)
, d = 1, . . . , D − 1,
where τˆd and Var(τˆd) are extracted from βˆ and Var(βˆ) respectively.
Next, we reject H0d if Td > e, with e chosen to control the FWER. Explicitly, using a Dunnett test
[3], we take e as the solution to
1− α = ΨD−1{(e, . . . , e)T ,Var(T ), νN}, (2.2)
where ΨM{x,Λ, ν} is the M -dimensional cumulative distribution function of a central multivariate t-
distribution with covariance matrix Λ and ν degrees of freedom. We take the degrees of freedom here, for
sample size N , to be νN = (N −1)(P −1)− (D−1), which arises from that associated with an analogous
multi-level ANOVA design. Moreover, Var(T ) is the covariance matrix of T = (T1, . . . , TD−1)>, which
can be calculated using Var(βˆ).
Now, in this case, if σ2e and σ
2
b were known, and we assumed that n1 = · · · = nK , we could derive a
simple formula for the total number of patients, N , required to achieve the desired power for the trial.
Here, we denote this formula using the function N(σ2e , σ
2
b ), explicitly stating it’s dependence upon the
within and between person variances. In the Appendix, we elaborate on how this formula can be derived.
Our problem, as discussed, is that in practice σ2e and σ
2
b are rarely known accurately at the design
stage. Therefore, we propose to re-estimate the required sample size at an interim analysis timed after
nint ∈ N patients. That is, we consider several methods to construct estimates, σˆ2e and σˆ2b , for σ2e and σ2b
respectively, based on the data accrued up to the interim analysis. Then, the final sample size for the
trial is taken as
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Nˆ =

nint if N(σˆ
2
e , σˆ
2
b ) ≤ nint,
dN(σˆ2e , σˆ2b )e if nint < N(σˆ2e , σˆ2b ) < nmax,
nmax if N(σˆ
2
e , σˆ
2
b ) ≥ nmax,
where dxe denotes the nearest integer greater than or equal to x and nmax ∈ N is a specified maximal
allowed sample size. It could be based, for example, on the cost restrictions or feasible recruitment rate
of a trial. Of course, if Nˆ = nmax then the trial will be expected to be under-powered. Thus, if necessary,
additional patients are recruited and a final analysis conducted as above based on the calculated values
of the test statistics Td, and the critical value e as defined in Equation (2.2).
Throughout, to give our function N(·) a simple form, we consider values of nint that imply an equal
number of patients could be allocated to each of the K sequences, and assume randomisation schemes
that ensures this is the case. Moreover, for reasons to be elucidated shortly, we consider from here only
settings where the K sequences are balanced for period. That is, across the chosen sequences, each
treatment appears an equal number of times in each period. We now proceed by detailing each of our
explored methods for estimating σ2e and σ
2
b based on the internal pilot data.
2.2. Unblinded estimator
The first of the methods we consider is an unblinded procedure. As noted, such an approach is typically
less well favoured by regulatory agencies. However, though this may not always actually prove to be
the case (see, e.g., Friede and Kieser [9]), one may anticipate its performance in terms of estimating
the key variance components and provided desired operating characteristics to be preferable to that of
the blinded procedures. This method therefore serves as a standard against which to assess the blinded
estimators. Explicitly, this approach breaks the randomisation code and fits the linear mixed model (2.1)
to the accrued data using REML estimation. With the REML estimates of σ2e and σ
2
b obtained, they are
utilised in the re-estimation procedure as described above.
2.3. Adjusted blinded estimator
Zucker et al. [34] considered a blinded estimator for two-arm parallel trial designs based on an adjustment
to the one-sample variance. Golkowski et al. [11] considered a similar unadjusted procedure for two-
arm bioequivalence trials. Here, we consider a similar approach for multi-treatment crossover trials.
Specifically, the following blinded estimators of the within and between person variances are used
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σˆ2e =
1
2(P − 1)(nint − 1)
P∑
j=2
K∑
k=1
nint/K∑
i=1
(pijk − p¯j)2
− nint
2K(P − 1)(nint − 1)
P∑
j=2
K∑
k=1
(τ∗d(j,k) − τ∗d(j−1,k))2,
σˆ2b =
1
2
 12(P − 1)(nint − 1)
P∑
j=2
K∑
k=1
nint/K∑
i=1
(qijk − q¯j)2 − σˆ2e
− nint
2K(P − 1)(nint − 1)
P∑
j=2
K∑
k=1
(τ∗d(j,k) + τ
∗
d(j−1,k))
2
+
2nint
D2(nint − 1)
(
K∑
k=1
τd(1,k)
)2 ,
for specified τ∗d , d = 0, . . . , D − 1, with τ∗0 = 0, where
pijk = yijk − yij−1k,
qijk = yijk + yij−1k,
p¯j =
1
nint
K∑
k=1
nint/K∑
i=1
pijk,
q¯j =
1
nint
K∑
k=1
nint/K∑
i=1
qijk.
In the Appendix, we show that if τ∗d = τd for d = 1, . . . , D − 1 then E(σˆ2e) = σ2e and E(σˆ2b ) = σ2b ,
and thus σˆ2e and σˆ
2
b are unbiased estimators for σ
2
e and σ
2
b respectively. This is the reason for our
restrictions on the employed randomisation scheme (which assumes n1 = · · · = nK = nint/K at the
interim reassessment), and the employed sequences (which are assumed to be balanced for period). The
above estimator could be used when there is imbalance in the number of patients allocated to each
sequence, or without making this restriction on the sequences, but results on the expected values of the
variance components would have a more complex form. It is therefore advantageous to ensure an equal
number of patients are allocated to each sequence, and also logical to utilise period balanced sequences.
We also view is as sensible therefore to explore the performance of the estimators in this case.
It is also important to assess the sensitivity of the performance of these estimators to the choice of
the τ∗d , hoping for it to have negligible impact as in analogous procedures for other trial settings [16].
Adapting previous works (see, e.g., Kieser and Friede [17], Zucker et al. [34], Gould and Shih [12]), we
assess this procedure for τ∗d = 0, and τ
∗
d = δ, d = 1, . . . , D − 1, and refer to these henceforth as the null
adjusted and alternative adjusted re-estimation procedures respectively.
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Note that one limitation of this approach in practice is that there is no guarantee that the above value
for σˆ2b will be positive. Therefore, we actually re-evaluate the required sample size as N{σˆ2e ,max(0, σˆ2b )}.
For the examples provided in the Appendix, we demonstrate that the above procedure still performs well
despite this inconvenience. Moreover, in certain routinely faced scenarios, as will be discussed shortly,
the value of σ2b is inconsequential and this issue therefore no longer exists. However, in general this must
be kept in mind when considering using this procedure for sample size re-estimation.
2.4. Blinded estimator following block randomisation
The above re-estimation procedures are explored within the context of a simple randomisation scheme that
only ensures an equal number of patients are allocated to each sequence prior to the interim re-assessment.
In contrast, the final blinded estimator we consider exploits the advantages block randomisation can bring,
extending the methodology presented in Xing and Ganju [31] for parallel arm trials to crossover studies.
We suppose that patients are allocated to sequences in B blocks, each of length nB (with these values
chosen such that BnB = nint). We recategorise our data as yijb, the response from patient i = 1, . . . , nB ,
in period j, in block b. Then, the following blinded estimators are used to recalculate the required sample
size
σˆ2e =
1
2(P − 1)(nint −B)
P∑
j=2
B∑
b=1
nB∑
i=1
(pijb − p¯jb)2,
σˆ2b =
1
2
 12(P − 1)(nint −B)
P∑
j=2
B∑
b=1
nB∑
i=1
(qijb − q¯jb)2 − σˆ2e
 ,
where
pijb = yijb − yij−1b,
qijb = yijb + yij−1b,
p¯jb =
1
nB
nB∑
i=1
pijb,
q¯jb =
nB∑
i=1
nB∑
i=1
qijb.
In the Appendix, provided that an equal number of patients are allocated to each of a set of period
balanced sequences, these are also shown to be unbiased estimators for σ2e and σ
2
b . Note though that
as above, we must actually re-estimate N using N{σˆ2e ,max(0, σˆ2b )}. Additionally, when using block
randomisation, the actual sample size used by a trial may differ from Nˆ , if it is not divisible by the block
length nB .
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3. Simulation study
3.1. Motivating examples
We present results for three motivating examples based on real crossover trials. Example 1 is described
in Section 3.2, with Examples 2 and 3 discussed in the Appendix, where their associated results are
also presented. Among the three examples we consider settings with a range of required sample sizes,
utilising complete block, incomplete block, and extra-period designs. This allows us to provide a thorough
depiction of the performance of the various estimators in a wide range of realistic trial design settings.
3.2. Example 1: TOMADO
First, we assess the performance of the various re-estimation procedures using the TOMADO trial as
motivation. TOMADO compared the clinical effectiveness of a range of mandibular devices for the
treatment of obstructive sleep-apnea hypopnea. Precise details can be found in Quinnell et al. [24].
Briefly, TOMADO was a four-treatment four-period crossover trial, with patients allocated treatment
sequences using two Williams squares. The data for the outcome Epworth Sleepiness Scale was to be
analysed using linear mixed model (2.1), with the following hypotheses tested
H0d : τd ≥ 0, H1d : τd < 0, d = 1, . . . , D − 1,
since a reduction in the Epworth Sleepiness Scale score is indicative of an efficacious treatment. Conse-
quently, the null hypotheses were to be rejected if Td < −e, using the value of e determined as above.
Following the methodology described in the Appendix, we can demonstrate that when complete-
block period-balanced sequences are used for treatment allocation, that the required sample size has no
dependence upon the between person variance σ2b . Explicitly, we have
N(σ2e , σ
2
b ) ≡ N(σ2e) =
2σ2e(z1−α∗ + z1−β)
2
δ2
,
where α∗ is defined in the Appendix. See Jones and Kenward [15], for an alternative derivation of this
formula. This substantially simplifies the re-estimation procedure, as we only need to provide a value for
σ2e , and do not require use of the estimators for σ
2
b .
TOMADOs complete case analysis estimated the following values for the various components of the
linear mixed model (1)
µˆ0 = 10.65, pˆi2 = −0.77, pˆi3 = −0.96, pˆi4 = −0.55,
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τˆ1 = −1.51, τˆ2 = −2.15, τˆ3 = −2.37, σˆ2e = 6.51, σˆ2b = 10.12.
Therefore, for σ2e = σˆ
2
e , the trials planned recruitment of 72 patients would have conferred power of 0.8 at
a significance level of 0.05 for δ = −1.24. Consequently, we set β = 0.2 and α = 0.05 throughout. In the
main manuscript, we additionally take δ = −1.24 and σ2b = 10.12 always. The effect of other underlying
values for δ and σ2b is considered in the Appendix. In contrast, whilst we focus here on the case with
σ2e = 6.51, we also consider the influence of alternative values for this parameter. When simulating data
we take µ0 = 10.65, pi2 = −0.77, pi3 = −0.96, and pi4 = −0.55. However, the effect of other period effects
is discussed in Section 4 and in the Appendix.
We explore the performance of the procedures under the global null hypothesis (τ1 = τ2 = τ3 = 0),
when only treatment one is effective (τ1 = δ, τ2 = τ3 = 0), when treatments one and two are effective
(τ1 = τ2 = δ, τ3 = 0), under the global alternative hypothesis (τ1 = τ2 = τ3 = δ), and under what we refer
to henceforth as the observed treatment effects (τ1 = −1.51, τ2 = −2.15, τ3 = −2.37). For simplicity, we
assume a single Latin square was used for treatment allocation, and set nmax = 1000 so that there is no
practical upper limit on the allowed sample size. In all cases, the average result for a particular design
and analysis scenario was determined using 100,000 trial simulations.
3.3. Distributions of σˆ2e and Nˆ
First, the performance of the re-estimation procedures was explored for the parameters listed in Sec-
tion 3.2, with σ2e = 6.51, and nint ∈ {8, 16, 24, 32, 40}. The resulting distributions of σˆ2e , the interim
estimate of σ2e , are shown in Figure 1 via the median, lower and upper quartiles in each instance. Addi-
tionally, Figure 2 depicts the equivalent results for the distribution of Nˆ , the interim re-estimated value
for N . The results are grouped according to the timing of the re-estimation and by the true value of the
treatment effects. Note that nB = 4 is only considered for values of nint which allows an equal number
of patients to be allocated to each sequence by the interim analysis.
The median value of σˆ2e for the unblinded procedure is always close to, but typically slightly less than,
the true value σ2e . The same statement holds for the block randomisation procedure with nB = 2 or
4. However, whilst this is true for the adjusted procedures under the global null hypothesis, it is not
otherwise always the case. In particular, both perform poorly for the observed treatment effects.
As would be anticipated, the alternative adjusted procedure has lower median values for σˆ2e than the
null adjusted procedure. Moreover, using the block randomised re-estimation procedure with nB = 4
seems to improve performance over nB = 2, both in terms of the median value of σˆ
2
e , and by imparting
a smaller interquartile range for σˆ2e .
The results for Nˆ mirror those for σˆ2e . Thus Nˆ is larger for the adjusted estimators under the observed
treatment effects, but otherwise the distributions are comparable.
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Increasing the value of nint reduces the interquartile range for σˆ
2
e and Nˆ for each procedure, and results
in median values closer to the truth, as would be expected. Finally, we observe that the interquartile
range for the unblinded procedure is often smaller than that of its adjusted or block randomisation
counterparts.
3.4. Familywise error-rate and power
For the scenarios from Section 3.3 that were not conducted under the observed treatment effects, the
estimated FWER and power were also recorded. The results are displayed in Table 1.
The FWER for each of the procedures is usually close to the nominal level, with a maximal value of
0.052 for the unblinded procedure with nint = 32. The adjusted procedures arguably have the smallest
inflation across the considered values of nint.
In most cases the re-estimation procedures attain a power close to the desired level. Of the adjusted
procedures, the null adjusted has a larger power, as would be anticipated given our observations on σˆ2e
and Nˆ above. In fact, the null adjusted method conveys the highest power for each value of nint. The
power of the block randomised procedures is typically similar to that of the alternative adjusted method.
In addition, whether only treatment one, treatments one and two, or all three treatments are effective
has little effect on the power.
There is no clear to trend as to the effect of increasing nint on the FWER, however it leads in almost
all instances to an improvement in power. Finally, increasing the value for nB in the block randomisation
procedure increases power as would be predicted.
3.5. Influence of σ2e
In this section, we consider the influence of the value of σ2e on the performance of our re-estimation
procedures. Specifically, whilst we know that increasing σ2e will increase the required sample size, we
would like to assess the effect this has upon the ability of the methods to control the FWER and attain
the desired power.
Figures 3 and 4 respectively present our results on the FWER and power of the various re-estimation
procedures when nint ∈ {16, 32} for several values of σ2e ∈ [0.25(6.51), 4(6.51)], under the global null and
alternative hypotheses respectively.
Arguably, we observe that the FWER is more variable for smaller values of σ2e , with it changing
little for several of the procedures when σ2e > 10. There is additionally some evidence to suggest that
increasing the value of nint reduces the overall effect σ
2
e has on the FWER.
For the power, as would be anticipated, the re-estimation procedures are over-powered when nint = 32
and σ2e is small. Moreover, increasing the value of nint universally increases the power. Finally, as σ
2
e
increases beyond approximately σ2e = 5, for both considered values of nint, there is little change in power.
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3.6. Sample size inflation factor
Whilst the above suggests the overall performance of the re-estimation is good, there are several simple
refinements that can be implemented to improve the observed results.
One such refinement, to help ensure the power provided by the re-estimation procedures is at least
the desired 1 − β, is to utilise a sample size inflation factor as originally proposed by Zucker et al. [34].
With it, the value of Nˆ as determined using the arguments above, is enlarged by the following factor
(
t1−α,νnint + t1−β,νnint
z1−α + z1−β
)2
.
Of course, one must be careful that the new implied sample size does not exceed any specified value of
nmax. However, this factor has then been shown to improve the performance of re-estimation procedures
in both superiority [34], non-inferiority [9], and two-treatment bioequivalence trials [11].
Figure 5 displays its effect in the context of our multi-treatment crossover trials. Explicitly, the
power of the various re-estimation procedures under the global alternative hypothesis, for nint ∈
{8, 16, 24, 32, 40} and σ2e = 6.51, is shown with and without the use of the inflation factor. For the
unblinded, null adjusted, and block randomised method with nB = 4, the inflation factor increases power
to above the desired level in every instance. Consequently, this simple inflation factor appears once more
to be an effective adjustment to the basic procedures.
4. Discussion
In this article, we have developed and explored several methods for the interim re-assessment of the
sample size required by a multi-treatment crossover trial. Our methodology is applicable to any trial
analysed using the linear mixed model (2.1), when there is equal participant allocation to a set of period
balanced sequences. Thus whilst adapting the work of Golkowski et al. [11] would be advisable in the
case of an AB/BA superiority trial, given that it does not require the use of simulation, our methods are
pertinent to a broader set of crossover designs. Indeed, they are as readily applicable to multi-treatment
superiority trials as they are ones for establishing bioequivalence.
We explored performance via three motivating examples, allowing consideration of settings with dif-
ferent types of sequences and a range of required sample sizes. Overall, the results presented here for the
TOMADO trial are similar to those provided in the Appendix for Examples 2 and 3. However, larger
inflation to the FWER was observed in Example 2, most likely as a consequence of its associated smaller
sample sizes. Nonetheless, the methods were found to provide desirable power characteristics with negli-
gible inflation to the FWER in many settings. In particular, the blinded procedures provided comparable
operating characteristics to the unblinded procedure, and thus can be considered viable alternatives.
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Following results for parallel arm trials [9], the null adjusted blinded estimator arguably performed bet-
ter than the other estimators in that its typical over-estimation of the variance at interim led to the
desired power being achieved more often. We may therefore tentatively suggest the null adjusted blinded
estimator to be the preferred approach in this setting.
Our findings indicate that for each of the re-estimation procedures, the choice of δ and the underlying
values of σ2e and σ
2
b often have little effect upon the FWER and power. We may be reassured therefore
that the performance of the procedures should often be relatively insensitive to the design parameters.
On a similar note, it is important to recognise that one cannot be certain when utilising these methods
that the value of the period effects will not influence the performance of the re-estimation procedures.
Whilst the final analysis should be asymptotically invariant to period effects, in finite samples it may
influence the results of the hypothesis tests. Intuitively though one would not anticipate this effect to be
large, nor would one routinely expect large period effects in many settings. In the Appendix, simulations
to explore this are presented for the TOMADO example. The results indicate that there is little evidence
to suggest the value of the period effects influences the performance of the re-estimation procedures.
Trialists must be mindful however that this cannot be guaranteed, and should therefore be investigated.
We also considered the utility of a simple sample size inflation factor in ensuring the power reaches the
desired level. Ultimately, we demonstrated that this was an effective extension to the basic re-estimation
procedures. Though the observed inflation to the FWER of our procedures was often small, if more
strict control is desired, a crude α-level adjustment procedure can also be utilised. For a particular
re-estimation scenario, the values of σ2e and σ
2
b , σ
2
e,max and σ
2
b,max say, which maximise the inflation to
the FWER under the global null hypothesis can be determined via a two dimensional search. Then, the
significance level used in the analysis of the trial can be adjusted to the αadj that confers a FWER of
α for this σ2e,max, σ
2
b,max pair, according to further simulations. This may be useful in practice if the
inflation is large for a particular trial design scenario of interest.
It is important to note the seemingly inherent advantages and disadvantages of the various re-
estimation procedures. The adjusted estimator is perhaps the most constrained of those considered;
requiring an equal number of patients to be allocated to each sequence for any non-zero adjustment to
be reasonable. This is particularly troubling because of the possibility of patient drop-out.
The estimator following block randomisation does not necessitate equal allocation to sequences
(though its performance was considered here only when this was the case), but could also fall foul of
patient drop-out that would prevent the estimation of the within person variance for each block. It also
requires block randomisation, and could not be used with a more simple randomisation scheme if this
was desired. The unblinded estimator of course suffers from none of these problems, but as discussed
may be looked upon less favourably by regulators.
Finally, note that in conducting our work we also considered the performance of two re-estimation
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procedures based on methodology for the clustering of longitudinal data [7, 10]. The motivation for
this came from the Expectation-Maximisation algorithm approaches of Gould and Shih [12] for parallel
two-arm, and Kieser and Friede [16] for parallel multi-arm, studies. These methods may seem appeal-
ing, as they are blinded, under certain assumptions can produce unbiased estimates of the variance
parameters, do not require specification of any adjustment, and in theory should be able to more readily
handle small amounts of missing data. However, we found that they routinely vastly under-estimated
the size of within person variance, resulting in substantially lower power than that attained by the other
re-estimation procedures. Accordingly, especially given the associated concerns about the appropriate-
ness of an Expectation-Maximisation algorithm for blinded sample size re-estimation [8], we would not
recommend re-estimation be performed based on a clustering based approach.
In conclusion, following findings for other trial design settings, blinded estimators can be used for
sample size re-estimation in multi-treatment crossover trials. The operating characteristics of any chosen
procedure should of course be assessed pre-trial through a comprehensive simulation study. But, often,
investigators can hope to find that the likelihood of correctly powering their study when there is pre-trial
uncertainty over the within and between person variances can be enhanced.
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A. Deriving N(σ2e , σ
2
b )
In this section, we elaborate on how a formulae for the sample size required by a trial, N(σ2e , σ
2
b ), can be
specified when σ2e and σ
2
b are known, a set of K sequences have been chosen, and n1 = · · · = nK . First,
we focus on the set up from Section 2.1, before briefly describing adjustments for other testing scenarios.
We begin by denoting the linear mixed model for our vector of observations y by y = Xβ +Zb+ .
Here, it is important to note that the particular form of the matrices X and Z is dependent on the
sample size and the chosen sequences. Then, the generalised least squares estimate for β, βˆ, is given by
βˆ = (X>Σ−1X)−1X>Σ−1y,
where Σ = ZGZ> + R is known. Precisely, by our choice of covariance structure implied by linear
mixed model (1), Σ will be an NP × NP block diagonal matrix, consisting of P × P blocks given by
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σ2eIP + σ
2
bJP . In addition, Var(βˆ) = (X
>Σ−1X)−1, will also be known. Finally, βˆ is an unbiased
estimate of β. Thus the vector of test statistics Q = (Q1, . . . , QD−1)>, where
Qd =
τˆd
{Var(τˆd)}1/2 , d = 1, . . . , D − 1,
has the following multivariate normal distribution
Q ∼ N
{
τ ◦ I1/2,Diag(I1/2)Var(τˆ )Diag(I1/2)
}
.
Here, τ = (τ1, . . . , τD−1)>, and I = (I1, . . . , ID−1)> with Id = {Var(τˆd)}−1. Furthermore, Diag(v) is
the matrix formed by placing the elements of the vector v along the leading diagonal, and we take the
convention that {(v1, . . . , vm)>}1/2 = (v1/21 , . . . , v1/2m )>.
Using the distribution of Q, we can control the FWER to a desired level α for our hypotheses of
interest by rejecting H0d if Qd > e, for the e which is the solution of
1− α = ΦD−1{(e, . . . , e)>,Var(Q)},
where ΦM{x,Λ} is the M -dimensional cumulative distribution function of a central multivariate normal
distribution with covariance matrix Λ. The power to reject H01 when τ1 = δ is then
Φ1{δI1/21 − Φ−11 (1− α∗, 1), 1},
for α∗ = 1− Φ1(e, 1). Consequently, to have power of 1− β we must have
Φ1{δI1/21 − Φ−11 (1− α∗, 1), 1} = 1− β.
By deriving the explicit form of I1 we can determine its dependence upon the sample size N , which allows
the above to be arranged and our final formula N(σ2e , σ
2
b ) specified.
For example, as discussed in Section 3.2, in the case where complete block sequences that are balanced
for period are utilised, it is well known that I1 = N/(2σ
2
e) (Jones and Kenward, 2014). Thus, we can
rearrange the above to acquire our previously specified formula
N(σ2e , σ
2
b ) ≡ N(σ2e) =
2σ2e{Φ−11 (1− α∗, 1) + Φ−11 (1− β, 1)}2
δ2
≡ 2σ
2
e(z1−α∗ + z1−β)
2
δ2
.
In the case where alternative hypotheses are to be assessed (e.g., a global test that foregoes many-to-
one comparisons), provided testing is performed using effects from βˆ, the above can easily be adapted to
designate an appropriate sample size formula. In each instance, one specifies a vector of test statistics, the
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distribution of which can be derived using that of βˆ. This allows an appropriate formulae for controlling
the FWER to be provided. For example, in the case where
H0d : τd = 0, H1d : τd 6= 0, d = 1, . . . , D − 1,
we still utilise Q as defined above, but now reject H0d if |Qd| > e, where e is the solution of
1− α/2 = ΦD−1{(e, . . . , e)>,Var(Q)}.
Then, a formulae for the power of interest can similarly be designated, which allows N to either be
specified explicitly, or permits an iterative search to be performed to determine its required value.
For example, for the design scenario of Section 2.1, if we instead desire a familywise power of at least
1− β when τ = (δ, . . . , δ)> (that is, power to reject at least one of H01, . . . ,H0D−1), our formula for the
power becomes
1− ΦD−1{(e− δI1/21 , . . . , e− δI1/2D−1)>,Var(Q)}.
Having derived I and Var(Q) for any N , a one-dimensional search can then be performed to acquire the
minimal N such that the above is at least 1− β.
B. Adjusted blinded estimator
In this section, we find the expected value of the adjusted blinded estimators of the within and between
person variances discussed in the main paper.
First, note that for any K sequences which are balanced for period
K∑
k=1
(τd(j,k) − τd(j−1,k)) = 0, (B.1)
for j = 2, . . . , P , and
K∑
k=1
τd(1,k) = · · · =
K∑
k=1
τd(P,k). (B.2)
Now note that for the linear mixed model (1) that
E(pijk) = pij − pij−1 + τd(j,k) − τd(j−1,k).
In addition, observe that Cov(pi1j1k1 , pi2j2k2) = 0 unless i1 = i2 and k1 = k2. Furthermore
Var(pijk) = Cov(yijk − yij−1k, yijk − yij−1k),
= Cov(yijk, yijk)− Cov(yijk, yij−1k)
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− Cov(yij−1k, yijk) + Cov(yij−1k, yij−1k),
= (σ2e + σ
2
b )− σ2b − σ2b + (σ2e + σ2b ),
= 2σ2e .
Consequently
E (p¯j) = E
 1
nint
K∑
k=1
nint/K∑
i=1
pijk
 ,
=
1
nint
K∑
k=1
nint/K∑
i=1
E(pijk),
=
1
nint
K∑
k=1
nint/K∑
i=1
(pij − pij−1 + τd(j,k) − τd(j−1,k)),
=
1
nint
nint(pij − pij−1),
= pij − pij−1,
where we have used Equation (3). Additionally
Var (p¯j) = Var
 1
nint
K∑
k=1
nint/K∑
i=1
pijk
 ,
=
1
n2int
Var
 K∑
k=1
nint/K∑
i=1
pijk
 ,
=
1
n2int

K∑
k=1
nint/K∑
i=1
Var (pijk) +
∑
k1 6=k2
∑
i1 6=i2
Cov (pi1jk1 , pi2jk2)
 ,
=
1
n2int

K∑
k=1
nint/K∑
i=1
Var (pijk)
 ,
=
1
n2int
(2σ2enint),
=
2σ2e
nint
.
Next, consider the following, which we call σ2within
σ2within =
1
2(P − 1)(nint − 1)
P∑
j=2
K∑
k=1
nint/K∑
i=1
(pijk − p¯j)2,
=
1
2(P − 1)(nint − 1)
P∑
j=2
 K∑
k=1
nint/K∑
i=1
p2ijk − nintp¯2j
 .
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Taking expectations we have
2(P − 1)(nint − 1)E(σ2within) =
P∑
j=2

K∑
k=1
nint/K∑
i=1
E
(
p2ijk
)− nintE (p¯2j)
 ,
=
P∑
j=2
 K∑
k=1
nint/K∑
i=1
{
Var(pijk) + E(pijk)
2
}
− nint
{
Var(p¯j) + E(p¯j)
2
} ,
=
P∑
j=2
 K∑
k=1
nint/K∑
i=1
{
2σ2e + (pij − pij−1 + τd(j,k) − τd(j−1,k))2
}
−nint
{
2σ2e
nint
+ (pij − pij−1)2
}]
,
=
P∑
j=2
2(nint − 1)σ2e +
K∑
k=1
nint/K∑
i=1
(pij − pij−1 + τd(j,k) − τd(j−1,k))2
− nint(pij − pij−1)2
 ,
= 2(P − 1)(nint − 1)σ2e
+
P∑
j=2

K∑
k=1
nint/K∑
i=1
(pij − pij−1)2 +
K∑
k=1
nint/K∑
i=1
(τd(j,k) − τd(j−1,k))2
+ 2(pij − pij−1)
K∑
k=1
nint/K∑
i=1
(τd(j,k) − τd(j−1,k))
− nint(pij − pij−1)2
 ,
= 2(P − 1)(nint − 1)σ2e
+
P∑
j=2
nint(pij − pij−1)2 +
K∑
k=1
nint/K∑
i=1
(τd(j,k) − τd(j−1,k))2
− nint(pij − pij−1)2
 ,
= 2(P − 1)(nint − 1)σ2e +
P∑
j=2
K∑
k=1
nint/K∑
i=1
(τd(j,k) − τd(j−1,k))2,
= 2(P − 1)(nint − 1)σ2e +
nint
K
P∑
j=2
K∑
k=1
(τd(j,k) − τd(j−1,k))2.
Thus we have that
E(σ2within) = σ
2
e +
nint
2K(P − 1)(nint − 1)
P∑
j=2
K∑
k=1
(τd(j,k) − τd(j−1,k))2,
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and for our adjusted blinded estimator
σˆ2e = σ
2
within −
nint
2K(P − 1)(nint − 1)
P∑
j=2
K∑
k=1
(τ∗d(j,k) − τ∗d(j−1,k))2,
it is clear that if τ∗d = τd for d = 1, . . . , D − 1 then E(σˆ2e) = σ2e , and σˆ2e is an unbiased estimator for σ2e
as claimed.
For the case where the sequences utilised for treatment allocation are additionally complete-block,
the above estimator for σ2e is all that is required by the adjusted blinded re-estimation procedures. When
this is not the case however, we further require a blinded estimate of the between person variance σ2b .
For this, define
qijk = yij−1k + yijk,
q¯j =
1
nint
K∑
k=1
nint/K∑
i=1
qijk.
Then, by a direct adaptation of the arguments above, and by using Equation (4), we can show that
E(qijk) = pij−1 + pij + τd(j−1,k) + τd(j,k),
Var(qijk) = 2(σ
2
e + 2σ
2
b ),
E(q¯j) = pij−1 + pij +
2
D
K∑
k=1
τd(1,k),
Var(q¯j) =
2(σ2e + 2σ
2
b )
nint
.
Now define
σ2between =
1
2(P − 1)(nint − 1)
P∑
j=2
K∑
k=1
nint/K∑
i=1
(qijk − q¯j)2.
Modifying the derivations for σ2within, we have that
E(σ2between) = σ
2
e + 2σ
2
b +
nint
2K(P − 1)(nint − 1)
P∑
j=2
K∑
k=1
(τd(j−1,k) + τd(j,k))2
+
2nint
D2(nint − 1)
(
K∑
k=1
τd(1,k)
)2
.
We can thus then take our blinded estimate for σ2b , σˆ
2
b , as
σˆ2b =
1
2
σ2between − σˆ2e − nint2K(P − 1)(nint − 1)
P∑
j=2
K∑
k=1
(τ∗d(j−1,k) + τ
∗
d(j,k))
2
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− 2nint
D2(nint − 1)
(
K∑
k=1
τ∗d(1,k)
)2 .
Again, in the case that τ∗d = τd for d = 1, . . . , D − 1, this is an unbiased estimator for σ2b .
C. Blinded estimator following block randomisation
Here, we first demonstrate the forwarded blinded estimator for σ2e following block randomisation is also
unbiased. Throughout, the index k above is essentially replaced by the index b. To begin, observe that
E(pijb) = pij − pij−1 + τdB(j,b) − τdB(j−1,b),
where dB(j, b) is the index of the treatment given to a patient in block b in period j. As above,
Cov(pi1j1b1 , pi2j2b2) = 0 unless i1 = i2 and b1 = b2, and Cov(pijb, pijb) = 2σ
2
e . Consequently
E (p¯jb) = E
(
1
nB
nB∑
i=1
pijb
)
,
=
1
nB
nB∑
i=1
E(pijb),
=
1
nB
nB∑
i=1
(pij − pij−1 + τdB(j,b) − τdB(j−1,b)),
=
1
nB
nB(pij − pij−1 + τdB(j,b) − τdB(j−1,b)),
= pij − pij−1 + τdB(j,b) − τdB(j−1,b),
Var (p¯jb) = Var
(
1
nB
nB∑
i=1
pijb
)
,
=
1
n2B
Var
(
nB∑
i=1
pijb
)
,
=
1
n2B

nB∑
i=1
Var (pijb) +
∑
i1 6=i2
Cov (pi1jb, pi2jb)
 ,
=
1
n2B
{
nB∑
i=1
Var (pijb)
}
,
=
1
n2B
(2σ2enB),
=
2σ2e
nB
.
Next consider the proposed blinded estimator
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σˆ2e =
1
2(P − 1)(nint −B)
P∑
j=2
B∑
b=1
nB∑
i=1
(pijb − p¯jb)2,
=
1
2(P − 1)(nint −B)
P∑
j=2
[
B∑
b=1
(
nB∑
i=1
p2ijb − nB p¯2jb
)]
.
We have
2(P − 1)(nint −B)E(σˆ2e) =
P∑
j=2
{
B∑
b=1
nB∑
i=1
E
(
p2ijb
)− nB B∑
b=1
E
(
p¯2jb
)}
,
=
P∑
j=2
[
B∑
b=1
nB∑
i=1
{
Var(pijb) + E(pijb)
2
}
− nB
B∑
b=1
{
Var(p¯jb) + E(p¯jb)
2
} ,
=
P∑
j=2
[
B∑
b=1
nB∑
i=1
{
2σ2e + (pij − pij−1 + τdB(j,b) − τdB(j−1,b))2
}
−nB
B∑
b=1
{
2σ2e
nB
+ (pij − pij−1 + τdB(j,b) − τdB(j−1,b))2
}]
,
=
P∑
j=2
[
2(nint −B)σ2e +
B∑
b=1
nB∑
i=1
(pij − pij−1 + τdB(j,b) − τdB(j−1,b))2
− nB
B∑
b=1
(pij − pij−1 + τdB(j,b) − τdB(j−1,b))2
 ,
=
P∑
j=2
[
2(nint −B)σ2e
]
,
= 2(P − 1)(nint −B)σ2e .
Thus E(σˆ2e) = σ
2
e , and the estimator is unbiased.
For non-complete-block treatment allocation, we can in this case take
σˆ2b =
1
2
 12(P − 1)(nint −B)
P∑
j=2
B∑
b=1
nB∑
i=1
(qijb − q¯jb)2 − σˆ2e
 .
To show this is unbiased, again without loss of generality consider the case where µ0 = 0. Then
E(qijb) = pij + pij−1 + τdB(j,b) + τdB(j−1,b),
Var(qijb) = 2(σ
2
e + 2σ
2
b ),
E(q¯jb) = pij + pij−1 + τdB(j,b) + τdB(j−1,b),
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Var(q¯jb) =
2(σ2e + 2σ
2
b )
nB
.
Using these results, a direct modification of the derivation for σˆ2e gives E(σˆ
2
b ) = σ
2
b .
D. Example 1: TOMADO
D.1. Introduction
In this section, we expand on our results from Section 3 on Example 1; the TOMADO trial. Throughout,
we set
µ0 = 10.65, σ
2
e = 6.51, α = 0.05, β = 0.2.
However, we now consider, in turn, the effect of altering the values of σ2b , δ, and the pij , from those used
in Section 3.
D.2. Influence of σ2b
First, we examine, in the case where pi2 = −0.77, pi3 = −0.96, pi4 = −0.55, and δ = −1.24, the influence
of the value of σ2b on the performance of the re-estimation procedures. As in Section 3.5, we would like
to ascertain the effect changing σ2b has upon the FWER and power.
Figures 6 and 7 respectively present our results on the FWER and power of the various re-estimation
procedures when nint ∈ {16, 32} for several values of σ2b ∈ [0.25(10.12), 4(10.12)], under the global null
and alternative hypotheses respectively.
As would be anticipated, the value of σ2b appears to have extremely little effect upon the performance
of each of the re-estimation procedures. Recall that this is a consequence of the fact that the complete
block sequences utilised in Example 1 render the requisite sample size independent of the between person
variance.
D.3. Influence of δ
Here, we consider the case where pi2 = −0.77, pi3 = −0.96, pi4 = −0.55, and σ2b = 10.12, focusing on the
influence δ has upon the procedures FWER and power. Precisely, Figures 8 and 9 respectively present
our findings for the FWER and power of the various re-estimation procedures when nint ∈ {16, 32} for
several values of δ ∈ [2(−1.24), 0.5(−1.24)], under the global null and alternative hypotheses respectively.
In Figure 8 we can see that there is no clear pattern to the effect on the FWER of changing δ, with
the fluctuations for several of the estimators relatively small. However, there is some evidence to suggest
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that increasing the value of δ (that is, making it closer to zero) reduces the FWER, as may be expected
as this implies a larger requisite sample size.
Similar statements are true for the power when examining Figure 9. Analogous to our discussions
around Figure 4, the re-estimation procedures are over-powered when nint = 32 and δ is large in magni-
tude. Furthermore, increasing the value of nint once more universally increases the power, whilst there
appears to be a point beyond which the power remains relatively constant.
D.4. Influence of period effects
In Section 4, we discussed how the influence of the period effects should be examined using simulation.
Again, though the final analysis on the trials data is asymptotically invariant to the true value of the
period effects, their value may influence the ability of the various re-estimation procedures to accurately
estimate the variance parameters at the interim reassessment. In this section, we assess the influence of
the value of the period effects on each of the re-estimation procedures. Explicitly, we consider the case
with nint = 16 and σ
2
e = 6.51, under the global null hypothesis. All others parameters are left as specified
in Section 3.2, except for the pij for j = 2, 3, 4. For these, in each replicate simulation we take
pij ∼ N(pˆij , σ2pi), j = 2, 3, 4.
That is, a value for each pij is drawn from a normal distribution with mean pˆij , and specified variance
σ2pi. We then assess the effect of the size of σ
2
pi upon the trials FWER and values for σˆ
2
e . Figures 10 and
11 display our findings. From them, it does appear that at least for this design scenario and associated
parameter set, the value of the period effects tends to have little influence on the interim estimation of
the within person variance, or on the trials FWER.
E. Example 2: Formoterol
E.1. Introduction
Senn (2002) reported the results of a double-blind placebo controlled cross-over trial to assess the perfor-
mance of two doses of formoterol solution aerosol (D = 3). Denoting the treatments by d = 0, 1, 2, with
d = 0 the placebo and d = 1, 2 corresponding to the two doses of formoterol, patients were allocated to
one of the following six incomplete block sequences
01, 10, 02, 20, 12, 21.
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We assume that the primary FEV1 (forced expiratory volume in 1 second) outcome data was to be
analysed with the linear mixed model (1), in order to test the following hypotheses
H0d : τd ≤ 0, H1d : τd > 0, d = 1, 2.
A complete case analysis of the data presented by Senn (2002) gives the following estimates for the
parameters in the model
µˆ0 = 1.51, pˆi2 = 0.03, τˆ1 = 0.50, τˆ2 = 0.52, σˆ
2
e = 0.053, σˆ
2
b = 0.49.
Consequently, for α = 0.1 and β = 0.2, a sample size of 30 patients would be powered to detect a clinically
relevant difference of δ = 0.2.
Accordingly, in this section we investigate the performance of the re-estimation procedures with the
various design parameters motivated by those obtained from the results of this formoterol trial. In
particular, this allows us to consider performance in a more challenging small sample setting. In all of
what follows we set µ0 = 1.51, pi2 = 0.03, α = 0.1 and β = 0.2, and we suppose that patients are allocated
treatments via one of the six sequences listed above (P = 2). We then consider in turn the effect of varying
one of the parameters σ2e , σ
2
b , and δ. As for Example 1, we will consider performance under the global
null hypothesis (τ1 = τ2 = 0), when only treatment one is effective (τ1 = δ, τ2 = 0), under the global
alternative hypothesis (τ1 = τ2 = δ), and under the observed treatment effects (τ1 = 0.50, τ2 = 0.52).
Moreover, we again take nmax = 1000, and estimate the average performance of each design and analysis
procedure using 100,000 trial simulations.
E.2. Distributions of σˆ2e , σˆ
2
b and Nˆ
We first examine the performance of the re-estimation procedures when σ2e = 0.053, σ
2
b = 0.49, and
δ = 0.2, for nint = 18. The resulting distributions of σˆ
2
e , σˆ
2
b , and Nˆ , are shown in Figures 12-14, via their
median, lower and upper quartiles across the simulations. The results are grouped according to the true
value of the treatment effects.
Following our findings for Example 1, the median values of σˆ2e , σˆ
2
b , and Nˆ for the unblinded and block
randomised procedures are always close to their respective true values. However, this is not always the
case for the adjusted estimators. In particular, the null adjusted estimator over-estimates the value of
σ2e when τ1 = δ, and the alternative adjusted procedure under estimates σ
2
e when τ1 = τ2 = 0. Both
adjusted estimators perform extremely badly at re-estimating σ2e under the observed treatment effects.
In terms of σˆ2b , the performance of the re-estimation procedures is more comparable, though the
adjusted procedures fair worse under the observed treatment effects.
As expected, the results for Nˆ once again mirror those for σˆ2e . This means, in particular, that the
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median value of Nˆ is substantially larger for the adjusted estimators under the observed treatment effects,
and is slightly larger for the null adjusted procedure when τ1 = δ.
Increasing the value of nint reduces the interquartile range for σˆ
2
e and Nˆ for each procedure, and results
in median values closer to the truth, as would be expected. Finally, we observe that the interquartile
range for the unblinded procedure is often smaller than that of its adjusted or block randomisation
counterparts.
E.3. Familywise error-rate, power, and sample size inflation factor
For the scenarios from Section S.M.5.2 that were not conducted under the observed treatment effects, the
estimated FWER and power were also recorded. Additional simulations were also performed to ascertain
the power of the procedures under the global alternative hypothesis when the sample size inflation factor
introduced in Section 3.6 was utilised. The results are displayed in Table 2.
We can see that the unblinded and block randomised procedures experience similar and substantial
inflation to the FWER. In contrast the adjusted procedures have an equal FWER with much smaller
inflation above the nominal level. Thus for this example, the small requisite sample size appears to have
inhibited the ability of the re-estimation procedures to retain a FWER close to α.
Each of the procedures attain the desired power apart from that utilising the alternative adjusted
estimator. The null adjusted estimator provides the largest power. These findings are not surprising
in light of the distributions of σˆ2e observed in Figure 12. Therefore in this instance the inflation factor
appears to only be of use to the alternative adjusted procedure.
E.4. Influence of σ2e
We now consider cases where σ2b = 0.49 and δ = 0.2, but σ
2
e 6= 0.053. Specifically, in Figures 15 and 16
we respectively examine the FWER and power of the re-estimation procedures under the global null and
alternative hypotheses when σ2e ∈ [0.25(0.053), 4(0.053)].
Figure 16 implies that the results for Example 2 are similar to those observed for Example 1. Explicitly,
when σ2e is very small the procedures are each over-powered, and as σ
2
e increases there appears to be less
of an effect upon the power.
In contrast, the results on the FWER displayed in Figure 15 depict a distinctive pattern for each of
the re-estimation procedures. Most likely, the observed peaks reflect a point at which the designs begin
to switch from terminating the trial at the interim reassessment, to continuing to the end of the second
stage. Overall, it is clear that the adjusted procedures typically have similar values of the FWER, with
the same true of the unblinded and block randomised procedures. Moreover, whilst all of the estimators
experience notable inflation to the FWER, it is smaller for the adjusted estimators, particularly as σ2e
increases.
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E.5. Influence of σ2b
Next, we examine scenarios where σ2e = 0.053 and δ = 0.2, but σ
2
b 6= 0.49: in Figures 17 and 18 we
respectively examine the FWER and power of the re-estimation procedures under the global null and
alternative hypotheses when σ2b ∈ [0.25(0.49), 4(0.49)].
Allowing for Monte Carlo error, it appears that the value of σ2b , as in Example 1, has negligible effect
upon the FWER and power of each of the the re-estimation procedures. This may seem surprising as we
specifically noted that a value for σ2b would be required to estimate the required sample size of a trial using
the incomplete block sequences specified in Section S.M.5.1. However, this result reflects two factors. The
first is that, as evidenced by Figure 13, the re-estimation procedures are very effective at estimating the
value of σ2b . More importantly, though, is that whilst the sample size required by the formoterol trial will
be dependent upon σ2b , it will still be principally driven by the value of σ
2
e . Therefore, the main driver of
the utility of the re-estimation procedures in this setting remains their ability to re-estimate the within
person variance.
E.6. Influence of δ
In our final investigations for Example 2 we consider scenarios in which σ2e = 0.053 and σ
2
b = 0.49,
but δ 6= 0.2. Precisely, in Figures 19 and 20 we respectively examine the FWER and power of the
re-estimation procedures under the global null and alternative hypotheses when δ ∈ [0.5(0.2), 2(0.2)].
Examining Figure 19, the FWER for the unblinded and block randomised procedures display the same
rising and falling shape as observed in Figure 15. In contrast, the FWER for the adjusted procedures
appears only to rise with in δ. This should not be surprising as larger values of δ imply smaller requisite
sample sizes, leaving the procedures prone to small sample size issues.
From Figure 20, as we would anticipate, for the larger considered values of δ the re-estimation proce-
dures are substantially over-powered. All but the alternative adjusted procedure still perform well though
when δ = 0.1.
F. Example 3: Hypertension
F.1. Introduction
Ebbutt (1984) presented an analysis of data from a two-treatment (D = 2) three-period (P = 3) crossover
hypertension trial. Denoting the treatments by d = 0, 1, patients were assigned to one of the following
four sequence groups
011, 100, 010, 101.
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Whilst Ebbutt (1984) assessed the data from only ten subjects on each sequence, Jones and Kenward
(2014) discussed the data from all patients who completed the trial. Here, we suppose that the data
Jones and Kenward (2014) presented on the outcome systolic blood pressure were to be analysed using
the linear mixed model (1) in order to test the following hypotheses
H01 : τ1 ≥ 0, H11 : τ1 < 0.
Thus, as in Example 1, a negative treatment effect implies efficacy.
In analysing the data from this trial using linear mixed model (1) we find
µˆ0 = 156.77, pˆi2 = −2.13, pˆi3 = −4.90, τˆ1 = −7.55, σˆ2e = 169.8, σˆ2b = 255.0.
Therefore, for α = 0.025, the trial’s sample size of 90 patients would provide power for a clinically relevant
difference of δ = −5.39 when β = 0.1.
In this section, we explore the performance of the re-estimation procedures with the parameters
motivated by the results of this hypertension trial. Thus, having considered complete block sequences in
Example 1, and incomplete block sequences in Example 2, we now consider a design utilising extra-period
sequences.
Following the same path as in Example 2, throughout what follows we set µ0 = 156.77, pi2 = −2.13,
pi3 = −4.90, α = 0.025 and β = 0.1, supposing that patients are allocated treatments based upon one
of the four sequences given above. We then again consider the effect of varying the parameters σ2e , σ
2
b ,
and δ. We examine performance under the null hypothesis (τ1 = 0), the alternative hypothesis (τ1 = δ),
and under the observed treatment effect (τ1 = −7.55). Finally, once more, we take nmax = 1000, and
estimate the average performance of each design and analysis procedure using 100,000 trial simulations.
F.2. Distributions of σˆ2e , σˆ
2
b and Nˆ
We first examine the performance of the re-estimation procedures when σ2e = 169.8, σ
2
b = 255.0, and
δ = −5.39, for nint ∈ {16, 32, 48}. The resulting distributions of σˆ2e , σˆ2b , and Nˆ , are shown in Figures 21-
23, via their median, lower and upper quartiles across the simulations. The results are grouped according
to the timing of the re-estimation and by the true value of the treatment effects.
Overall, the results are very similar to those of Examples 1 and 2. In particular, the unblinded and
block randomised procedures typically perform well in terms of re-estimating σ2e , whilst the adjusted
estimators performance is highly dependent on the value of τ1.
As in Example 1, increasing the value of nB for the block randomised procedure appears advantageous.
Moreover, as expected, increasing the value of nint reduces the distance between the median values of σˆ
2
e ,
σˆ2b , and Nˆ and their respective true values, whilst also reducing the interquartile range.
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In this case, the distributions of the σˆ2b are comparable across the procedures, regardless of the value
of nint or τ1.
Once more, the results for Nˆ largely reflect those for σˆ2e . However, the median values for Nˆ are larger
when using the block randomised procedure with nB = 8. This is a consequence of the fact that by
our assumptions an entire additional block of patients will be recruited even when a smaller number of
patients are required to attain the requisite sample size.
F.3. Familywise error-rate and power
For the scenarios from Section S.M.6.2 that were not conducted under the observed treatment effect, the
estimated FWER and power were also recorded. The results are displayed in Table 3.
In this instance, we observe that the FWER is in many instances slightly below the nominal level, with
a maximal value of only 0.0252 for the block randomised procedure with nB = 4 when nint ∈ {16, 48}.
This is likely a result of the fact that the number of observations accrued in each of the designs is, for a
crossover trial at least, large relative to the number of hypotheses that are to be tested.
Most of the re-estimation procedures attain a power close to the nominal level. However, the alterna-
tive adjusted estimator again leads to lower levels of power. Finally, as would be anticipated, increasing
the value of nint improves the power of the re-estimation procedures. However, it has no clear effect upon
the FWER.
F.4. Influence of σ2e
We now consider cases where σ2b = 255.0, and δ = −5.39, but σ2e 6= 169.8. Specifically, in Figures 24
and 25 we respectively examine the FWER and power of the re-estimation procedures under the null and
alternative hypotheses when σ2e ∈ [0.25(169.8), 4(169.8)].
Here, there appears to be some evidence that the smallest considered values of σ2e result in lower
values of the FWER. This may once more reflect a change between terminating the trial at the interim
reassessment and continuing to the end of the second stage. Nonetheless, is it clear that in this case the
procedures control the FWER well regardless of the value of the within person variance.
Similarly, whilst the smallest values of σ2e lead to the designs being substantially over-powered, it is
evident that when σ2e is increased they are still able to provide approximately the desired power.
F.5. Influence of σ2b
Next, we examine scenarios in which σ2e = 169.8, and δ = −5.39, but σ2b 6= 255.0: in Figures 26 and
27 we respectively examine the FWER and power of the re-estimation procedures under the null and
alternative hypotheses when σ2b ∈ [0.25(255.0), 4(255.0)].
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Similar to both Examples 1 and 2, allowing for Monte Carlo error, the value of σ2b seems to have little
effect upon the ability of the re-estimation procedures to control the FWER to 0.025, and to provide
power at level 0.9. We therefore have further evidence that we do not need to be concerned about the
underlying between patient variance when considering the appropriate use of the proposed methods.
F.6. Influence of δ
We now investigate settings in which σ2e = 169.8 and σ
2
b = 255.0, but δ 6= −5.39. Precisely, in Figures
28 and 29 we respectively examine the FWER and power of the re-estimation procedures under the null
and alternative hypotheses when δ ∈ [2(−5.39), 0.5(−5.39)].
Our results indicate that in this case, the smallest considered values of δ appear to result in reduced
values of the FWER. However, regardless of the value of δ, each of the procedures is generally able to
control the FWER to approximately the nominal level.
From Figure 29, we once more observe that when the magnitude of δ is large, the designs are over-
powered, but outside of this region the specified clinically relevant difference appears to have little effect
upon the power.
F.7. Sample size inflation factor
Our final consideration is to once more examine the utility of the sample size inflation factor introduced
in Section 3.6. In Figure 30 we present the power of the re-estimation procedures under the alternative
hypothesis, when nint ∈ {16, 32, 48}, with and without the use of the inflation factor.
As was observed for Example 1, the inflation factor leads to a notable boost in power, helping several
of the estimators achieve the desired performance. Therefore, when there are concerns around attaining
the desired power, we may again recommend that investigators consider utilising this simple adjustment.
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Table 1: The estimated familywise error-rate (FWER) is shown for each of the considered re-estimation
procedures and several values of nint under the global null hypothesis, for Example 1. Corresponding
values of the power when only treatment one is effective, treatments one and two are effective, or under
the global alternative hypothesis when all three experimental treatments are effective, are also shown.
The Monte Carlo error of the FWER and power values is approximately 0.0007 and 0.0013 respectively
in each instance. All figures are given to four decimal places.
Power
Re-estimation procedure nint FWER τ = (δ, 0, 0) τ = (δ, δ, 0) τ = (δ, δ, δ)
Unblinded 8 0.0513 0.7704 0.7694 0.7687
Null Adjusted 8 0.0496 0.7743 0.7809 0.7753
Alt. Adjusted 8 0.0500 0.7440 0.7512 0.7432
Block rand. with nB = 2 8 0.0509 0.7443 0.7455 0.7428
Unblinded 16 0.0506 0.7906 0.7893 0.7867
Null Adjusted 16 0.0512 0.7956 0.8010 0.7942
Alt. Adjusted 16 0.0495 0.7702 0.7731 0.7691
Block rand. with nB = 2 16 0.0512 0.7720 0.7723 0.7747
Block rand. with nB = 4 16 0.0525 0.7858 0.7887 0.7868
Unblinded 24 0.0509 0.7963 0.7934 0.7950
Null Adjusted 24 0.0496 0.8019 0.8071 0.7990
Alt. Adjusted 24 0.0508 0.7776 0.7793 0.7770
Block rand. with nB = 2 24 0.0504 0.7821 0.7838 0.7835
Unblinded 32 0.0520 0.7977 0.7962 0.7988
Null Adjusted 32 0.0509 0.8055 0.8109 0.8072
Alt. Adjusted 32 0.0498 0.7772 0.7857 0.7812
Block rand. with nB = 2 32 0.0514 0.7907 0.7879 0.7887
Block rand. with nB = 4 32 0.0511 0.8014 0.8002 0.8035
Unblinded 40 0.0516 0.7967 0.8010 0.8000
Null Adjusted 40 0.0504 0.8081 0.8115 0.8062
Alt. Adjusted 40 0.0498 0.7828 0.7858 0.7842
Block rand. with nB = 2 40 0.0518 0.7914 0.7926 0.7942
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Table 2: The estimated familywise error-rate (FWER) is shown for each of the considered re-estimation
procedures under the global null hypothesis, for Example 2. Corresponding values of the power when only
treatment one is effective, under the global alternative hypothesis when both experimental treatments
are effective, and under the global alternative hypothesis with use of the sample size inflation factor, are
also shown. The Monte Carlo error of the FWER and power values is approximately 0.001 and 0.0013
respectively in each instance. All figures are given to four decimal places.
Power
Re-estimation procedure FWER τ = (δ, 0) τ = (δ, δ) τ = (δ, δ) with Inf. Fac.
Unblinded 0.1174 0.8027 0.8047 0.8276
Null Adjusted 0.1069 0.8204 0.8186 0.8450
Alt. Adjusted 0.1069 0.7490 0.7485 0.7710
Block rand. with nB = 3 0.1157 0.8013 0.8029 0.8273
Table 3: The estimated familywise error-rate (FWER) and power is shown for each of the considered
re-estimation procedures and several values of nint under the null and alternative hypotheses respectively,
for Example 3. The Monte Carlo error of the FWER and power values is approximately 0.0005 and 0.001
respectively in each instance. All figures are given to four decimal places.
Re-estimation procedure nint FWER Power
Unblinded 16 0.0243 0.8761
Null Adjusted 16 0.0243 0.8758
Alt. Adjusted 16 0.0237 0.8517
Block rand. with nB = 4 16 0.0252 0.8696
Unblinded 32 0.0247 0.8913
Null Adjusted 32 0.0239 0.8895
Alt. Adjusted 32 0.0240 0.8712
Block rand. with nB = 4 32 0.0247 0.8876
Block rand. with nB = 8 32 0.0241 0.8942
Unblinded 48 0.0246 0.8961
Null Adjusted 48 0.0242 0.8946
Alt. Adjusted 48 0.0242 0.8744
Block rand. with nB = 4 48 0.0252 0.8946
Block rand. with nB = 8 48 0.0249 0.9007
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Figure 1: The distribution of σˆ2e is shown for each of the re-estimation procedures for several values of
τ , and several values of nint, for Example 1. Precisely, for each scenario, the median, lower and upper
quartile values of σˆ2e across the simulations are given. The dashed line indicates the true value of σ
2
e .
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Figure 2: The distribution of Nˆ is shown for each of the re-estimation procedures for several values of
τ , and several values of nint, for Example 1. Precisely, for each scenario, the median, lower and upper
quartile values of Nˆ across the simulations are given. The dashed line indicates the true required value
of N .
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Figure 3: The simulated familywise error-rate (FWER) is shown under the global null hypothesis for
each of the re-estimation procedures when nint ∈ {16, 32}, as a function of the within person variance
σ2e , for Example 1. The Monte Carlo error is approximately 0.0007 in each instance. The dashed line
indicates the desired value of the FWER.
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Figure 4: The simulated power is shown under the global alternative hypothesis for each of the re-
estimation procedures when nint ∈ {16, 32}, as a function of the within person variance σ2e , for Example
1. The Monte Carlo error is approximately 0.0013 in each instance. The dashed line indicates the desired
value of the power.
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Figure 5: The influence of the considered inflation factor upon the power of the re-estimation procedures
under the global alternative hypothesis is shown for several values of nint, for Example 1. The dashed
line indicates the desired value of the power.
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Figure 6: The simulated familywise error-rate (FWER) is shown under the global null hypothesis for
each of the re-estimation procedures when nint ∈ {16, 32}, as a function of the between person variance
σ2b , for Example 1. The Monte Carlo error is approximately 0.0007 in each instance. The dashed line
indicates the desired value of the FWER.
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Figure 7: The simulated power is shown under the global alternative hypothesis for each of the re-
estimation procedures when nint ∈ {16, 32}, as a function of the within person variance σ2b , for Example
1. The Monte Carlo error is approximately 0.0013 in each instance. The dashed line indicates the desired
value of the power.
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Figure 8: The simulated familywise error-rate (FWER) is shown under the global null hypothesis for each
of the re-estimation procedures when nint ∈ {16, 32}, as a function of the clinically relevant difference
δ, for Example 1. The Monte Carlo error is approximately 0.0007 in each instance. The dashed line
indicates the desired value of the FWER.
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Figure 9: The simulated power is shown under the global alternative hypothesis for each of the re-
estimation procedures when nint ∈ {16, 32}, as a function of the clinically relevant difference δ, for
Example 1. The Monte Carlo error is approximately 0.0013 in each instance. The dashed line indicates
the desired value of the power.
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Figure 10: The distribution of σˆ2e is shown under the global null hypothesis for each of the re-estimation
procedures when nint = 16, as a function of the variance of the period effects σ
2
pi, for Example 1. Precisely,
for each scenario, the median, lower and upper quartile values of σˆ2e across the simulations are given. The
dashed line indicates the true value of σ2e .
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Figure 11: The simulated familywise error-rate (FWER) is shown under the global null hypothesis for
each of the re-estimation procedures when nint = 16, as a function of the variance of the period effects
σ2pi, for Example 1. The Monte Carlo error is approximately 0.0007 in each instance. The dashed line
indicates the desired value of the FWER.
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Figure 12: The distribution of σˆ2e is shown for each of the re-estimation procedures for several values of
τ , for Example 2. Precisely, for each scenario, the median, lower and upper quartile values of σˆ2e across
the simulations are given. The dashed line indicates the true value of σ2e .
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Figure 13: The distribution of σˆ2b is shown for each of the re-estimation procedures for several values of
τ , for Example 2. Precisely, for each scenario, the median, lower and upper quartile values of σˆ2b across
the simulations are given. The dashed line indicates the true value of σ2b .
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Figure 14: The distribution of Nˆ is shown for each of the re-estimation procedures for several values of
τ , for Example 2. Precisely, for each scenario, the median, lower and upper quartile values of Nˆ across
the simulations are given. The dashed line indicates the true required value of N .
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Figure 15: The simulated familywise error-rate (FWER) is shown under the global null hypothesis for
each of the re-estimation procedures, as a function of the within person variance σ2e , for Example 2. The
Monte Carlo error is approximately 0.001 in each instance. The dashed line indicates the desired value
of the FWER.
l
l
l
l
l l
l l
l
l
l
l
l
l
l l l
l
l
l
l
l
l l
l l
l
l
l
l
l
l
l l l
l
Unblinded Null Adjusted Alt. Adjusted Block with n_B = 3
0.05 0.10 0.15 0.20 0.05 0.10 0.15 0.20 0.05 0.10 0.15 0.20 0.05 0.10 0.15 0.20
0.75
0.80
0.85
0.90
0.95
σe
2
Po
w
e
r
Figure 16: The simulated power is shown under the global alternative hypothesis for each of the re-
estimation procedures, as a function of the within person variance σ2e , for Example 2. The Monte Carlo
error is approximately 0.0013 in each instance. The dashed line indicates the desired value of the power.
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Figure 17: The simulated familywise error-rate (FWER) is shown under the global null hypothesis for
each of the re-estimation procedures, as a function of the within person variance σ2b , for Example 2. The
Monte Carlo error is approximately 0.001 in each instance. The dashed line indicates the desired value
of the FWER.
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Figure 18: The simulated power is shown under the global alternative hypothesis for each of the re-
estimation procedures, as a function of the within person variance σ2b , for Example 2. The Monte Carlo
error is approximately 0.0013 in each instance. The dashed line indicates the desired value of the power.
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Figure 19: The simulated familywise error-rate (FWER) is shown under the global null hypothesis for
each of the re-estimation procedures, as a function of the clinically relevant difference δ, for Example 2.
The Monte Carlo error is approximately 0.001 in each instance. The dashed line indicates the desired
value of the FWER.
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Figure 20: The simulated power is shown under the global alternative hypothesis for each of the re-
estimation procedures, as a function of the clinically relevant difference δ, for Example 2. The Monte
Carlo error is approximately 0.0013 in each instance. The dashed line indicates the desired value of the
power.
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Figure 21: The distribution of σˆ2e is shown for each of the re-estimation procedures for several values of
τ , and for several values of nint, for Example 3. Precisely, for each scenario, the median, lower and upper
quartile values of σˆ2e across the simulations are given. The dashed line indicates the true value of σ
2
e .
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Figure 22: The distribution of σˆ2b is shown for each of the re-estimation procedures for several values of
τ , and several values of nint, for Example 3. Precisely, for each scenario, the median, lower and upper
quartile values of σˆ2e across the simulations are given. The dashed line indicates the true value of σ
2
e .
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Figure 23: The distribution of Nˆ is shown for each of the re-estimation procedures for several values of
τ , and several values of nint, for Example 3. Precisely, for each scenario, the median, lower and upper
quartile values of Nˆ across the simulations are given. The dashed line indicates the true required value
of N .
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Figure 24: The simulated familywise error-rate (FWER) is shown under the global null hypothesis for
each of the re-estimation procedures when nint ∈ {32, 48}, as a function of the within person variance
σ2e , for Example 1. The Monte Carlo error is approximately 0.0005 in each instance. The dashed line
indicates the desired value of the FWER.
51
ll l l l l l ll
l
l
l l l l l ll
l
l
l
l
l l l ll
l
l
l l l l l ll
l
l
l
l l l l ll
l
l
l
l l l l ll
l
l
l
l
l l l ll
l
l
l
l l l l ll
n_int = 32 n_int = 48
Unblinded
N
ull Adjusted
Alt. Adjusted
Block w
ith n_B = 4
200 400 600 200 400 600
0.80
0.85
0.90
0.95
1.00
0.80
0.85
0.90
0.95
1.00
0.80
0.85
0.90
0.95
1.00
0.80
0.85
0.90
0.95
1.00
σe
2
Po
w
e
r
Figure 25: The simulated power is shown under the global alternative hypothesis for each of the re-
estimation procedures when nint ∈ {32, 48}, as a function of the within person variance σ2e , for Example
1. The Monte Carlo error is approximately 0.001 in each instance. The dashed line indicates the desired
value of the power.
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Figure 26: The simulated familywise error-rate (FWER) is shown under the global null hypothesis for
each of the re-estimation procedures when nint ∈ {32, 48}, as a function of the within person variance
σ2b , for Example 3. The Monte Carlo error is approximately 0.0005 in each instance. The dashed line
indicates the desired value of the FWER.
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Figure 27: The simulated power is shown under the global alternative hypothesis for each of the re-
estimation procedures when nint ∈ {32, 48}, as a function of the within person variance σ2b , for Example
3. The Monte Carlo error is approximately 0.001 in each instance. The dashed line indicates the desired
value of the power.
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Figure 28: The simulated familywise error-rate (FWER) is shown under the global null hypothesis for each
of the re-estimation procedures when nint ∈ {32, 48}, as a function of the clinically relevant difference
δ, for Example 3. The Monte Carlo error is approximately 0.0005 in each instance. The dashed line
indicates the desired value of the FWER.
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Figure 29: The simulated power is shown under the global alternative hypothesis for each of the re-
estimation procedures when nint ∈ {32, 48}, as a function of the clinically relevant difference δ, for
Example 3. The Monte Carlo error is approximately 0.001 in each instance. The dashed line indicates
the desired value of the power.
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Figure 30: The influence of the considered inflation factor upon the power of the re-estimation procedures
under the global alternative hypothesis is shown for several values of nint, for Example 3. The dashed
line indicates the desired value of the power.
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